Clinical Trial

A Phase II Study on Adjuvant Vaccination with Dendritic Cells Loaded with Autologous Tumor Homogenate in Resected Stage IV Rare Cancers.

Study acronym: RaC-Ad
Recruiting Phase 2
View on ClinicalTrials.gov →
Summary
Single-arm, monocentric trial to assess safety and immunological efficacy of adjuvant vaccination with autologous dendritic cells loaded with autologous tumour homogenate after curative resection for stage IV rare cancers (In Head/Neck tumors (H\&N), NEuroendocrine Tumors (NET) and Soft Tissue Sarcomas (STS).
Protocol Amendment History 3 amendments
This ClinicalTrials.gov record has been amended 3 times since 2019-11-14; most recent amendment 2024-09-17.
Status change: Not Yet Recruiting → Recruiting 2020-04-20
Trial Details
NCT Number NCT04166006
Lead Sponsor Istituto Romagnolo per lo Studio dei Tumori Dino Amadori IRST S.r.l. IRCCS
Conditions Head Neck Tumors, Neuroendocrine Tumors, Soft Tissue Sarcoma, Rare Cancer, Vaccination
Enrollment 51 participants
Start Date 2019-12-12
Primary Completion 2027-04 (estimated)
Study Completion 2031-12 (estimated)
Updated on ClinicalTrials.gov 2024-09-19